SLC5A2 and type 2 diabetes mellitus: In recent years, the effectiveness and safety of SGLT-2 inhibitors in treating patients with type 2 diabetes and mild to moderate renal insufficiency (eGFR ≥ 30 mL/min/1.73 m2) have been confirmed through large clinical trials such as EMPA-REG OUTCOMES (82), DECLARE-TIME 58 (83), CANVAS-R (84), and CREDENCE (85).